Monday, February 10, 2025 11:00:26 PM
We're all entitled to our opinions, but you're telling me nothing about sales of DCVax-L or the earnings the company should be seeing.
I'll admit the company won't get rich on 1000 batches a year, even at $250,000 which they roughly get for compassionate care it's not all that much, $250,000,000 for which they'd be lucky to see more than $100 million in earning.
If a P/E of 30 did apply and 1.5 billion shares outstanding it's still a $2 share price. I think it will be far better as I don't think the EDEN will be that long and I also suspect that they can make more with an approved product than it's sold for in compassionate use, but the company want to keep cost down, so I really don't know what they're looking for.
Gary
I'll admit the company won't get rich on 1000 batches a year, even at $250,000 which they roughly get for compassionate care it's not all that much, $250,000,000 for which they'd be lucky to see more than $100 million in earning.
If a P/E of 30 did apply and 1.5 billion shares outstanding it's still a $2 share price. I think it will be far better as I don't think the EDEN will be that long and I also suspect that they can make more with an approved product than it's sold for in compassionate use, but the company want to keep cost down, so I really don't know what they're looking for.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
